Loading...

A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

The most prevalent lung cancer, non-small cell lung cancer (NSCLC) has receptors for vasoactive intestinal peptide (VIP). Here the effects of a VIP antagonist (VIP-hyb) on NSCLC growth were investigated. In vivo, when VIPhyb (10 micrograms, s.c.) was daily injected into nude mice, xenograft formatio...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Moody, T W, Zia, F, Draoui, M, Brenneman, D E, Fridkin, M, Davidson, A, Gozes, I
Format: Artigo
Sprog:Inglês
Udgivet: 1993
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC46507/
https://ncbi.nlm.nih.gov/pubmed/8389448
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!